Patents For AIDS Drugs Would Hike Prices Without India Safeguards
This article was originally published in PharmAsia News
If patents are granted in India for AIDS drugs, their cost could increase so much HIV patients in the country could have problems getting them, the government said. But the Union Minister of State for Chemicals and Fertilisers also said India's Patent Act contains safeguards against that event. The country also has access to anti-retrovirals in bulk from international companies bidding to supply the drugs, the minister said. India also has an agreement with an international agency to supply free AVR drugs for children and other second-line ARV drugs that would be administered for free. (Click here for more
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.